Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-001 (AT-001) in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease
2024-519497-39-00Phase 2Authorised
- Sponsor
- Arctic Therapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing NPI-001 with Placebo (2 arms). Planned start May 2025; status: authorised.
02
Drugs
N-acetylcysteine amide
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2024-519497-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519497-39-00.